MMA
FBRX icon

Miracle Mile Advisors’s Forte Biosciences FBRX Stock Holding History

Miracle Mile Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-27
Closed -$5K – 287
2019
Q4 		$5K Hold
27
– – ﹤0.01% 298
2019
Q3 		$7K Buy
+27
New +$41K ﹤0.01% 277

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Miracle Mile Advisors's FBRX Position: Q1 2020 in Review

Miracle Mile Advisors sold out of Forte Biosciences (FBRX) in Q1 2020, closing a stake of 27 shares — an estimated $5K sold.

Miracle Mile Advisors first reported a position in FBRX in Q3 2019 and held it in 2 quarters. The position peaked at $7K in Q3 2019. 50 funds tracked by Wall St. Rank hold FBRX as of Q1 2020.

  • Miracle Mile Advisors reported no remaining Forte Biosciences position as of Q1 2020 after selling out during the quarter.
  • Miracle Mile Advisors sold 27 Forte Biosciences shares in Q1 2020, an estimated $5K.
  • Miracle Mile Advisors first reported a position in Forte Biosciences in Q3 2019 and held it in 2 quarters.
  • Miracle Mile Advisors's Forte Biosciences position peaked at $7K in Q3 2019.
  • 50 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2020.

Based on Miracle Mile Advisors's 13F filing for Q1 2020, filed 11 May 2020.